Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and SpringWorks Therapeutics, Inc., a Stamford, Connecticut- based commercial-stage biopharmaceutical company focused on ...

SpringWorks’ portfolio complements Merck KGaA, Darmstadt, Germany’s progress in rare tumors, with Merck KGaA, Darmstadt, Germany recently exercising an option for worldwide commercialization ...

Merck KGaA acquires SpringWorks Therapeutics for $3.9B to enhance its cancer drug portfolio, boosting revenue growth and strengthening U.S. market presence.

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE:MRK) for $47 per share in cash. The ...

Merck said the bid represented a premium of 26% to SpringWorks’ unaffected 20-day average price of $37.38 on February 7, before Reuters disclosed potential for a transaction.

Shares in SpringWorks jumped Monday after Reuters reported that the company was in talks with Merck, closing 34% higher. This gave the Stamford, Conn.-based company a market value of $4.02 billion ...

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business Provided by Business Wire Apr 27, 2025, 11:11:00 PM ...

In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark “Merck” internationally.